Surveilling the Potential for Precision Medicine-driven PD-1/PD-L1-targeted Therapy in HNSCC

Mann, JE; Hoesli, R; Michmerhuizen, NL; Devenport, SN; Ludwig, ML; Vandenberg, TR; Matovina, C; Jawad, N; Mierzwa, M; Shuman, AG; Spector, ME; Brenner, JC

doi:10.7150/jca.17547



International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

Global reach, higher impact

Full Text | PDF

J Cancer 2017; 8(3):332-344. doi:10.7150/jca.17547 This issue Cite

Review

Surveilling the Potential for Precision Medicine-driven PD-1/PD-L1-targeted Therapy in HNSCC

JE Mann^1,2*, R Hoesli^1*, NL Michmerhuizen^1,3, SN Devenport^1,6, ML Ludwig^1,4, TR Vandenberg¹, C Matovina¹, N Jawad¹, M Mierzwa^5,6, AG Shuman^1,6#, ME Spector^1,6#, JC Brenner^1,6#✉

1. Department of Otolaryngology - Head and Neck Surgery, University of Michigan Medical School, Ann Arbor, MI.
2. Department of Pathology, University of Michigan Medical School, Ann Arbor, MI.
3. Department of Pharmacology, University of Michigan Medical School, Ann Arbor, MI.
4. Program in Cellular and Molecular Biology, University of Michigan Medical School, Ann Arbor, MI.
5. Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, MI.
6. Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI.
*Authors contributed equally.
^#Authors are co-senior on this paper.

Citation:

Mann JE, Hoesli R, Michmerhuizen NL, Devenport SN, Ludwig ML, Vandenberg TR, Matovina C, Jawad N, Mierzwa M, Shuman AG, Spector ME, Brenner JC. Surveilling the Potential for Precision Medicine-driven PD-1/PD-L1-targeted Therapy in HNSCC. J Cancer 2017; 8(3):332-344. doi:10.7150/jca.17547. https://www.jcancer.org/v08p0332.htm

Other styles

Abstract

Immunotherapy is becoming an accepted treatment modality for many patients with cancer and is now approved for use in platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Despite these successes, a minority of patients with HNSCC receiving immunotherapy respond to treatment, and few undergo a complete response. Thus, there is a critical need to identify mechanisms regulating immune checkpoints in HNSCC such that one can predict who will benefit, and so novel combination strategies can be developed for non-responders. Here, we review the immunotherapy and molecular genetics literature to describe what is known about immune checkpoints in common genetic subsets of HNSCC. We highlight several highly recurrent genetic lesions that may serve as biomarkers or targets for combination immunotherapy in HNSCC.

Keywords: Genetics, Immunotherapy, EGFR, personalized medicine, HNSCC.

Citation styles

APA

Mann, JE., Hoesli, R., Michmerhuizen, NL., Devenport, SN., Ludwig, ML., Vandenberg, TR., Matovina, C., Jawad, N., Mierzwa, M., Shuman, AG., Spector, ME., Brenner, JC. (2017). Surveilling the Potential for Precision Medicine-driven PD-1/PD-L1-targeted Therapy in HNSCC. Journal of Cancer, 8(3), 332-344. https://doi.org/10.7150/jca.17547.

ACS

Mann, JE.; Hoesli, R.; Michmerhuizen, NL.; Devenport, SN.; Ludwig, ML.; Vandenberg, TR.; Matovina, C.; Jawad, N.; Mierzwa, M.; Shuman, AG.; Spector, ME.; Brenner, JC. Surveilling the Potential for Precision Medicine-driven PD-1/PD-L1-targeted Therapy in HNSCC. J. Cancer 2017, 8 (3), 332-344. DOI: 10.7150/jca.17547.

NLM

CSE

Mann JE, Hoesli R, Michmerhuizen NL, Devenport SN, Ludwig ML, Vandenberg TR, Matovina C, Jawad N, Mierzwa M, Shuman AG, Spector ME, Brenner JC. 2017. Surveilling the Potential for Precision Medicine-driven PD-1/PD-L1-targeted Therapy in HNSCC. J Cancer. 8(3):332-344.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.